InVivo Therapeutics completes enrollment in study of Nuero-Spinal Scaffold

[Image from InVivo]InVivo Therapeutics (Nasdaq:NVIV) announced today that it completed enrollment in the Inspire 2.0 study for patients with acute spinal cord injury.

Cambridge, Massachusetts-based InVivo’s 20-patient randomized, controlled trial aims to enhance the clinical evidence for the company’s Neuro-Spinal Scaffold.

The company designed the Neuro-Spinal Scaffold to encourage functional cells to fill a cavity that will typically develop at the site of a spinal cord injury if left untreated. The scaffold is implanted at the site of damage within one week of spinal cord injury to support neural regeneration and cell growth.

If the platform achieves this, the structural change within the spinal cord could potentially improve sensory and motor function and lead to better quality of life for the patient.

“Reaching full enrollment in our Inspire 2.0 study is a significant advancement in our research and development efforts towards a pote…

Read more
  • 0